missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD5/CD20 Antibody Cocktail, FITC, PE

Descrizione
This antibody is a monoclonal mixture of FITC-conjugated CD5 (clone M28623, isotype IgG2a) and PE-conjugated CD20 (clone DFA-7, isotype IgG1).
In humans, CD5 is a 67kDa T lymphocyte single chain transmembrane glycoprotein. It is present on all mature T lymphocytes, on most of thymocytes and on many T cell leukemias and lymphomas. It reacts with a subpopulation of activated B cells. The CD20 antigen is present on human pre-B lymphocytes and on B-lymphocytes atall stage of maturation, except on plasma cells. Low level expression of the CD20 antigen has been detected on normal T lymphocytes. CD20 is a non glycosylated protein with a molecular weight of 35 or 37 kDa depending on the degree of phosphorylation.
Specifica
Specifica
| Antigene | CD5/CD20 |
| Applicazioni | Flow Cytometry |
| Classificazione | Cocktail |
| Clone | M28623, DFA-7, DFA-7 |
| Coniugato | FITC/PE |
| Formulazione | PBS with 0.2% carrier protein and 0.08% sodium azide |
| Gene | MS4A1 |
| N. accesso geni | P06127, P11836 |
| Alias gene | B1; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; B-lymphocyte surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; CD5; CD5 antigen (p56-62); CD5 antigen p56-62; CD5 molecule; CVID5; LEU1; LEU-16; Leukocyte surface antigen Leu-16; lymphocyte antigen T1/Leu-1; membrane spanning 4-domains A1; membrane-spanning 4-domains subfamily A member 1; membrane-spanning 4-domains, subfamily A, member 1; MGC3969; MS4A1; MS4A2; S7; T1; T-cell surface glycoprotein CD5 |
| Simboli geni | CD5, MS4A1 |
| Vedi altri risultati |
Titolo del prodotto
Facendo clic su Invia, l'utente riconosce che potrebbe essere contattato da Fisher Scientific in merito al feedback fornito in questo modulo. Non condivideremo le vostre informazioni per altri scopi. Tutte le informazioni di contatto fornite saranno conservate in conformità con la nostra Politica sulla privacy. Informativa sulla privacy.
Individuate un'opportunità di miglioramento?